6 completed, 1 active not recruiting, 1 recruiting. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Inventiva Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Global Research Initiative for Patients Screening on MASH MASH, MASLD | Recruiting | Julius Clinical | 10000 | 2023-06-30 | 2024-08-01 | |
| Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus Lanifibranor, Placebo, Empagliflozin - NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2 | Phase 2 | Completed | Inventiva Pharma | 39 | 2022-06-29 | 2026-09-09 |
| A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) IVA337, Placebo - NASH - Nonalcoholic Steatohepatitis | Phase 3 | Active not recruiting | Inventiva Pharma | 1000 | 2021-08-19 | 2026-11-02 |
| Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose Moxifloxacin, Placebo, Lanifibranor - Healthy Subjects | Phase 1 | Completed | Inventiva Pharma | 36 | 2019-01-17 | 2019-11-01 |
| Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease Lanifibranor, Placebo - Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM) | Phase 2 | Completed | University of Florida | 128 | 2018-08-14 | 2024-09-19 |
| A Study in MPS VI to Assess Safety and Efficacy of Odiparcil Odiparcil, Placebo - Mucopolysaccharidosis VI | Phase 2 | Completed | Inventiva Pharma | 20 | 2017-12-30 | 2019-11-01 |
| Phase 2b Study in NASH to Assess IVA337 IVA337, Placebo - Non-Alcoholic Steatohepatitis (NASH) | Phase 2 | Completed | Inventiva Pharma | 247 | 2017-02-07 | 2023-07-19 |
| Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis IVA337, Placebo - Scleroderma, Diffuse, Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Completed | Inventiva Pharma | 145 | 2015-10-29 | 2019-03-04 |
Non-alcoholic Fatty Liver Disease (4) · Diabetes Mellitus, Type 2 (3) · Fatty Liver (2) · Fibrosis (2) · Liver Diseases (2) · Digestive System Diseases (1) · Hypertension (1) · Liver Cirrhosis (1) · Metabolic Syndrome (1) · Mucopolysaccharidosis VI (1) · Obesity (1) · Scleroderma, Diffuse (1)
lanifibranor (6) · Moxifloxacin (1) · empagliflozin (1) · odiparcil (1)
France (6) · Germany (6) · United Kingdom (5) · Belgium (4) · Italy (4) · Netherlands (4) · Spain (4) · United States (4) · Bulgaria (3) · Czechia (3) · Poland (3) · Portugal (3) · Australia (2) · Canada (2) · Slovenia (2)
Arun J Sanyal, MD (1) · Christopher Denton, Professor (1) · Diederick E. Grobbee, MD/PhD/FESC (1) · Kenneth Cusi, MD (1) · Manuel Castro Cabezas, MD/PhD (1) · Oscar H. Franco, MD/PhD/FESC/FFPH (1) · Sven Francque, MD (1) · Yannick Allanore, Professor (1)
PMID 33038502, PMID 34670042, PMID 38730247, PMID 39824443, PMID 40107637, PMID 40447415
2016 (1), 2018 (1)